Skip to content

Pipeline Fueled by Bold Science

Merakris is developing a pipeline of first-in-class regenerative therapy candidates designed to combat a broad range of diseases with high unmet clinical needs. Our immediate focus is on the therapeutic area of complex wound healing including venous leg ulcers (VLUs) and diabetic foot ulcers (DFUs).

Our Pipeline Overview

Merakris' pipeline

Clinical Trial for Venous Leg Ulcer

VLUs account for


of all venous disease linked leg ulcerations

Prevalence of VLUs


Number of Americans with VLUs



of VLUs progress to chronic wounds

*Probst, S., Weller, C.D., Bobbink, P. et al. Prevalence and incidence of venous leg ulcers—a protocol for a systematic review. Syst Rev 10, 148 (2021).

The high prevalence and severe complications of VLUs underscore the immediate need for more effective therapeutic solutions.

Merakris’ Dermacyte Amniotic Wound Care Liquid is currently being studied in a Phase II clinical trial for the treatment of non-healing venous leg ulcers.

Another Area of Focus

Another area of immediate focus at Merakris Therapeutics is in the treatment of non-healing chronic Diabetic Foot Ulcers (DFU).

Diabetics have


lifetime risk of developing DFU

 DFU patients have


lifetime incidence of lower-extremity amputation

5-year DFU mortality rate


McDermott K, Fang M, Boulton AJM, Selvin E, Hicks CW. Etiology, Epidemiology, and Disparities in the Burden of Diabetic Foot Ulcers. Diabetes Care. 2023 Jan 1;46(1):209-221. doi: 10.2337/dci22-0043. PMID: 36548709; PMCID: PMC9797649.